Does novel oral anticoagulant improve anticoagulation for non‐valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai

Chronic Diseases and Translational Medicine - Tập 1 - Trang 203-209 - 2015
Feng-Di Liu1, Rong Zhao1, Xue-Mei Wang1, Shuo Wang1, Xiao-Lei Shen1, Xiao-Xiao Tao1, Bo Zheng1, Jia-Li Peng1, Hui Zhang1, Ran Mo1, Yan Tong1, Wen-Ting Li1, Xiao-Yan Feng1, Ge-Fei Li1, Liang Shu1, Jian-Ren Liu1
1Department of Neurology and Jiuyuan Municipal Stroke Center, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

Tóm tắt

AbstractsObjectiveTo summarize the use rate, safety, efficacy of antithrombotics in stroke/transient ischemic attack (TIA) prevention, and reasons for not using dabigatran etexilate (DE) in Shanghai, China.MethodsNon‐valvular atrial fibrillation (NVAF)‐associated stroke patients were prospectively registered as an electronic database. Use rate of antithrombotics and reasons for not using DE were extracted during follow‐up. Patients' baseline characteristics, recurrent ischemic stroke/TIA events and bleeding complications were analyzed.PatientsFrom April 2012 to August 2014, 110 inpatients with NVAF‐associated stroke were studied in our hospital. NVAF was diagnosed by 12‐lead electrocardiogram, 24 h Holter and echocardiography.ResultsBefore introduction of DE (April 2013), use rates of warfarin and antiplatelets were 28.9% (11/38) and 60.5% (23/38) respectively; after that, use rates of warfarin, DE, and antiplatelets were 20.8% (15/72), 12.5% (9/72), and 43.1% (31/72). The DE did not improve use of anticoagulants (P = 0.639). There were 19 (17.3%) recurrent ischemic stroke events up to October 2015; two (9.5%) in the non‐user group, 10 (18.5%) in the antiplatelet group, and seven (20.0%) in the anticoagulants group (P = 0.570). Furthermore, recurrence rates were similar between the DE group (20.0%) and the Warfarin group (20.0%, P = 1.000). The most common reason for not using DE was financial concerns (61.0%), followed by inconvenience to purchase (14.0%) and hemorrhage concerns (11.0%). Two patients using warfarin found fecal occult blood so they stopped warfarin and began to use antiplatelet drugs. No bleeding event occurred in the other groups. Only one patient had side effects (dyspepsia and gastroesophageal reflux) from DE.ConclusionThe use rate of either DE or warfarin in Shanghai was low; DE had not improved anticoagulation therapy for NVAF patients in Shanghai mainly because DE had not been covered by health insurance.

Tài liệu tham khảo

10.1093/europace/euq350 10.1016/S0140-6736(11)61514-6 10.1016/j.hrthm.2013.03.017 10.1161/CIRCULATIONAHA.105.595140 10.1093/eurheartj/eht280 10.1038/nrcardio.2014.118 10.1111/cns.12021 Aguilar M.I., 2005, Oral anticoagulants for preventing stroke in patients with non‐valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks, Cochrane Database Syst Rev, 3 10.1111/joim.12272 10.1177/0003319714536980 10.1093/europace/eus305 10.1161/CIR.0000000000000040 10.1345/aph.1R515 10.1016/j.ahj.2012.02.008 10.1016/j.amjmed.2015.07.013 10.1016/j.jstrokecerebrovasdis.2013.10.006 10.1056/NEJMoa0905561 10.1056/NEJMoa1009638 10.1056/NEJMoa1107039 10.1056/NEJMoa1310907 10.1160/TH13-11-0948 10.1093/europace/euu225 10.2165/11206400-000000000-00000 10.1371/journal.pone.0101245 10.1016/j.jacc.2013.03.020 10.1016/S0140-6736(07)61233-1 10.7326/0003-4819-146-12-200706190-00007 10.1161/STROKEAHA.112.664144 10.1111/ijs.12150 10.1161/STROKEAHA.111.000402 10.3111/13696998.2014.953682
Thông tin
Thông tin xuất bản

Chronic Diseases and Translational Medicine

Tập 1

203-209

Thông tin tác giả